Continuous Glucose Monitors Cross 11.4 Million US Users in Q1 2026 With Stelo and Lingo Driving Non-Diabetic Adoption

Continuous glucose monitors crossed 11.4 million active US users in Q1 2026, according to Wearable Health Industry Association data published April 18. That figure is up from 6.8 million in Q1 2025 and 3.4 million in Q1 2024. The expansion came from non-diabetic users for the first time in the category's history. Roughly 4.7 million of the Q1 2026 users had no diagnosis of diabetes or prediabetes. The opening came from FDA over-the-counter clearance of two consumer products. Dexcom Stelo received OTC clearance in March 2024 and launched commercially in August 2024. Abbott Lingo received OTC clearance in June 2024 and launched in September 2024.

Pricing settled into a clear tier structure. Stelo runs $99 for a two-sensor pack at retail, which provides 30 days of monitoring. Lingo runs $89 for a two-sensor pack. Levels Health, which uses prescription Abbott Libre 3 sensors and pairs them with software analysis, runs $199 for a two-sensor monthly subscription with annual commitment. NutriSense, a competing software platform, runs $250 monthly. Insurance coverage for non-diabetic CGM use remains rare. Out-of-pocket pay covers approximately 96 percent of consumer CGM users.

The clinical evidence for non-diabetic CGM use is mixed and worth understanding. Three categories of research have published meaningful findings. Glycemic variability research, which measures how much blood sugar fluctuates over a day, has shown CGM users can reduce variability by following high-fiber diets, exercising after meals, and avoiding ultra-processed foods. A 2024 randomized controlled trial published in Nature Medicine covering 142 healthy adults wearing CGMs for 14 days found measurable reductions in post-meal glucose spikes for participants who received behavioral coaching versus those who only saw their data. The improvement size was small but statistically significant.

Weight loss research is less supportive. A 2024 study from Stanford and University of Colorado Anschutz published in JAMA Internal Medicine covering 247 overweight non-diabetic adults randomized to CGM plus standard diet coaching versus standard diet coaching alone found no statistically significant difference in 6-month weight loss between groups. Both groups lost roughly 7 to 9 pounds on average. The CGM group reported higher engagement with food tracking and higher self-reported awareness of dietary patterns, but those did not translate into measurable additional weight loss.

The third research category is metabolic syndrome prevention. A long-running study at Tulane University published in February 2026 followed 1,124 adults with metabolic syndrome risk factors over 18 months, half wearing CGMs continuously and half receiving standard care. The CGM group showed measurable improvements in fasting glucose, HbA1c, and triglycerides versus the control group, with effect sizes of 7 to 14 percent across measures. The findings support CGM use for people with insulin resistance markers but not yet diabetes diagnoses.

What the marketing oversells matters for consumers. CGM marketing often suggests glucose spikes after meals are inherently harmful in non-diabetic adults. The clinical literature does not support that framing for healthy people. Post-meal glucose excursions of 30 to 60 mg per deciliter above baseline are normal physiological responses to mixed meals, especially carbohydrate-containing meals. Healthy non-diabetic adults clear those excursions within 60 to 120 minutes through normal insulin function. The presence of post-meal spikes in healthy adults is not a marker of disease.

What CGM use does deliver for non-diabetic users is behavioral feedback. Users report eating more vegetables and protein with meals, reducing late-night eating, and increasing post-meal walking after seeing their data. These are reasonable habits that improve health regardless of whether the underlying glucose patterns indicate any pathology. The CGM acts as a behavior modification device more than a diagnostic tool for healthy adults.

The integrations that arrived in 2025 and 2026 changed the user experience meaningfully. Stelo connected with Apple Health, Garmin Connect, Whoop, and Oura platforms. Lingo connected with the same set plus Google Fit and Strava. Levels and NutriSense both maintain proprietary apps but added Apple Health and Google Fit export. The integration with sleep and recovery tracking platforms allows users to correlate glucose patterns with sleep quality, exercise timing, and HRV. The integrated data view is what most users describe as the most valuable part of CGM use, more so than glucose readings alone.

For Wesley Insider readers thinking about wearing a CGM, the honest answer depends on goals. Anyone with insulin resistance, prediabetes, gestational diabetes history, or family history of type 2 diabetes has solid clinical reasons to use a CGM short term. Anyone curious about how their body responds to specific foods or training protocols can get useful behavioral feedback from a 30 to 60 day trial. Anyone using CGMs to chase flat glucose curves as a goal in itself is likely overreaching the science.

The next product in the category is implantable CGMs from Senseonics with one-year wear time, which received CE Mark in Europe in 2024 and is in FDA review for US launch in 2026. Pricing is expected to run $1,200 to $1,800 per year for self-pay non-diabetic users. The longer wear time eliminates the friction of monthly sensor changes that limits current consumer adoption.